Log In
Print
BCIQ
Print
Print this Print this
 

buprenorphine (Probuphine)

  Manage Alerts
Collapse Summary General Information
Company Titan Pharmaceuticals Inc.
DescriptionSubcutaneous rod implant for continuous 6-month delivery of buprenorphine using ProNeura technology
Molecular Target Mu opioid receptor (MOR) (OPRM1)
Mechanism of ActionMu opioid receptor agonist
Therapeutic ModalityMedical Devices: Drug/device combination
Latest Stage of DevelopmentPhase III
Standard IndicationAddiction
Indication DetailsTreat opioid dependence
Regulatory Designation U.S. - Priority Review (Treat opioid dependence)
Partner Braeburn Pharmaceuticals S.p.r.l.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$239.4M

$15.8M

$215.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today